Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Combination Use of Treanda Plus Calquence Shows Promise in Mantle Cell Lymphoma Subset

February 17th 2019, 8:00pm

Article

The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma.

Treatment Landscape Continues to Evolve in Mantle Cell Lymphoma

February 16th 2019, 7:00pm

Article

In patients with mantle cell lymphoma, the introduction of BTK inhibitors continues to shape the treatment landscape.

Examining Overtreatment in Mantle Cell Lymphoma

January 29th 2019, 9:18pm

Article

While some high-risk patients with mantle cell lymphoma may benefit from aggressive initial therapy, a recent study found that this may not be necessary for others who could benefit from more targeted therapies.

Zanubrutinib Granted Breakthrough Designation for Mantle Cell Lymphoma

January 15th 2019, 7:09pm

Article

The Food and Drug Administration (FDA) has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one prior therapy, according to BeiGene, the company manufacturing the agent.

Investigational BTK Inhibitor Sparks Responses in Patients with Mantle Cell Lymphoma

December 26th 2018, 8:00pm

Article

The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial.

Circulating Tumor DNA Serves as Early Predictor in Mantle Cell Lymphoma Outcomes

December 11th 2018, 9:41pm

Article

Measuring circulating tumor DNA in the blood of patients with advanced mantle cell lymphoma may be a viable way to predict how well they will respond to specific therapies.

Feasibility of Post-Transplant Velcade in Mantle Cell Lymphoma Encourages Further Study

December 10th 2018, 10:19pm

Article

Treatment with Velcade (bortezomib) following induction chemotherapy and stem cell transplantation seemed safe and effective for untreated patients with mantle cell lymphoma, encouraging further evaluation for more active, less toxic targeted agents.

Two Are Better Than One: Alternating Chemoimmunotherapy Regimens May Benefit Those with MCL

December 7th 2018, 2:00am

Article

A recent study looked at a new combination to determine what would happen if untreated patients eligible for transplant were given alternating cycles of Rituxan plus bendamustine and Rituxan plus cytarabine as induction therapy. The study pooled findings from two clinical trials and real-world experience.

Clinical Trial Results Leave Treatment Questions Unanswered for Certain Lymphomas

November 13th 2018, 7:45pm

Article

Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.

Single Agent Entospletinib Induces Modest Activity in Lymphoma Subgroups

November 13th 2018, 6:59pm

Article

Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.